Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Willemze, R ^a   Dreyling, M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEXAROTENE; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; GEMCITABINE; INTERFERON; METHOTREXATE; PREDNISONE; PSORALEN DERIVATIVE; RETINOID; RITUXIMAB; STEROID; VINCRISTINE; VORINOSTAT;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER STAGING; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; DRUG RESPONSE; ELECTRON THERAPY; HUMAN; LOW DRUG DOSE; MYCOSIS FUNGOIDES; PHOTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUVA; SEZARY SYNDROME; SKIN LYMPHOMA; SKIN SURGERY; UNSPECIFIED SIDE EFFECT;

CYTOSTATIC AGENTS; EUROPE; FOLLOW-UP STUDIES; HUMANS; INTERFERONS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; PROGNOSIS; PUVA THERAPY; RADIOTHERAPY; RETINOIDS; SKIN NEOPLASMS; STEROIDS; TREATMENT OUTCOME;

EID: 77954330749     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq183     Document Type: Article

References (17)

1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Olsen EA, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Study Group of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
3. Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Study Group of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.
4. Kaye FJ, Bunn PA, Steinberg SM et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Eng J Med 1989; 321: 784-790.
5. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003; 149: 1095-1107.
6. Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-1030.
7. Marchi E, Alinari L, Tani M et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005; 104: 2437-2441.
8. Quereux G, Marques S, Nguyen JM et al. Prospective multicenter study of pegylated liposomal doxorubicin in patients with advanced or refractory mycosis fungoides or Sezary syndrome. Arch Dermatol 2008; 144: 727-733.
9. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
10. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-388.
11. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Tansplant 2008; 41: 597-604.
12. Russell-Jones R. Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br J Dermatol 2000; 142: 16-21.
13. Bernengo MG, Quaglino P, Comessatti A et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007; 92: 784-794.
14. Bekkenk M, Geelen FAMJ, van Voorst Vader PC et al. Primary and secondary cutaneous CD30-positive lymphoproliferative disorders: long term follow-up data of 219 patients and guidelines for diagnosis and treatment. A report from the Dutch Cutaneous Lymphoma Group. Blood 2000; 95: 3653-3661.
15. Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification and prognostic factors. An EORTC Cutaneous Lymphoma Group study of 83 cases. Blood 2008; 111: 838-845.
16. Senff NJ, Noordijk EM, Kim YH et al. EORTC/ISCL consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112: 1600-1609.
17. Grange F, Maubec E, Bagot M et al. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab. Arch Dermatol 2009; 145: 329-330.